Zydus Lifesciences Ltd.

NSE: ZYDUSLIFE | BSE: 532321 | ISIN: INE010B01027 | Industry: Pharmaceuticals
| Turnaround Potential
1189.9000 -16.10 (-1.33%)
NSE Nov 13, 2026 15:31 PM
Volume: 805.1K
 

logo
Zydus Lifesciences Ltd.
21 Nov 2019
1189.90
-1.33%
Business Line
Cadila Healthcare said it has received approval from the US health regulator to market Isosorbide Dinitrate tablets used to prevent attacks of chest p
Zydus Lifesciences L.. has an average target of 1133.33 from 3 brokers.
USFDA approves Zydus Cadila's Dinitrate tablets, Desonide Cream
Business Line | 21 Nov 2019 1 more
More from Zydus Lifesciences Ltd.
Recommended
Not all revenue beats are equal: inside Q2’s biggest surprises
The Baseline | 13 Nov 2026, 06:04PM
Five Interesting Stocks Today - November 13, 2026
The Baseline | 13 Nov 2026, 05:47PM
Earnings Call Transcript - Cadila Healthcare
| 14 Feb 2020